Washington Dc, DCNCT05443126Now EnrollingIRB Ready

RET-altered Cancer Clinical Trial in Washington Dc, DC

Access cutting-edge ret-altered cancer treatment through this phase 1/2 clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.

Sponsored by Ellipses Pharma

Quick Self-Assessment

See if you qualify for this Washington Dc location

Preparing your pre-screening questions…

Expert Care in Washington Dc

Access ret-altered cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ret-altered cancer treatment provided free

Apply for This Washington Dc Location

Check if you qualify for this ret-altered cancer clinical trial in Washington Dc, DC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Washington Dc

    Convenient for DC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Washington Dc site if eligible
  4. 4Begin participation

About This RET-altered Cancer Study in Washington Dc

The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies (NSCLC)

Sponsor: Ellipses Pharma

Who Can Participate

Inclusion Criteria

Applicable to all participants:
Must be ≥18 years of age, with documented RET-altered NSCLC
Participants should be well informed and consented about alternative treatment options including approved RET-targeted therapies
ECOG performance status of 0 or 1 and life expectancy \>3 months at screening
Ability to understand and provide written informed consent and able to participate in all required evaluations and procedures
Measurable disease defined by RECIST v1.1
Must have locally advanced or metastatic NSCLC with RET fusion who are eligible to receive platinum-based doublet chemotherapy.
First line patients: Must not have received a Selective RET inhibitor or chemotherapy. Prior adjuvant and neo-adjuvant therapies (chemotherapy, radiotherapy, immunotherapy, biologic therapy, investigational agents), or definitive radiation/chemoradiation with or without regimens including immunotherapy, biologic therapy, investigational agents, are permitted as long as treatment was completed at least 12 months prior. Palliative radiotherapy for symptom management (eg, bone metastases) is permitted up to 2 weeks prior to treatment start.

Exclusion Criteria

Participants with any of the following will not be included in the study:
Any known major driver gene alterations other than RET.
Spinal cord compression or brain metastases. Patients with stable brain metastases can be enrolled.
Active infection requiring systemic antibiotic, antifungal, or antiviral medication
Severe or uncontrolled medical condition or psychiatric condition
Chronic glomerulonephritis or renal transplant
Participants with active hepatitis B infection or active hepatitis C
Participants with active HIV infection. Patients living with HIV may be eligible if they have adequate CD4+ T-cell count and no history of AIDS-defining opportunistic infections in the past 12 months
Receipt of any strong inhibitor or inducer of CYP3A4
Impaired hepatic or renal function, inadequate bone marrow reserve or organ function
Any clinically important abnormalities in rhythm, conduction, or morphology on resting ECG or any factor that increases the risk of QTc prolongation or of arrhythmic events , or congestive heart failure Grade III-IV according to the New York Heart Association, myocardial infarction, or unstable angina within the previous 6 months
Uncontrolled hypertension
Corneal ulceration or untreated keratitis at screening

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Washington Dc?

Yes, this clinical trial (NCT05443126) has an active research site in Washington Dc, DC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

RET-altered Cancer Treatment Options in Washington Dc, DC

If you're searching for ret-altered cancer treatment options in Washington Dc, DC, this clinical trial (NCT05443126) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Washington Dc research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced ret-altered cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ret-altered cancer clinical trials near you to find additional studies recruiting in your area.

More Essential Tremor Trials in Washington Dc, DC

See all essential tremor clinical trials recruiting in Washington Dc — not just this study.

Browse Essential Tremor Trials in Washington Dc →

Browse More Trials by Condition

Essential Tremor TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Washington Dc?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Washington Dc, DC